Bank Of New York Mellon Corp Bio Atla, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$2.3 - $8.25 $46,002 - $165,008	20,001 New	20,001 $53.6 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $125,806 - $220,211	20,001 New	20,001 $165,000
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $38,661 - $156,090	13,150 New	13,150 $101,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $108,118 - $273,088	-50,760 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$4.38 - $18.78 $13 - $56	-3 Reduced 0.01%	50,760 $254,000
Q4 2021 Feb 11, 2022	BUY	$19.0 - $30.95 $131,974 - $214,978	6,946 Added 15.85%	50,763 $996,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $378,127 - $561,796	12,844 Added 41.47%	43,817 $1.29 Million
Q2 2021 Aug 11, 2021	SELL	$38.07 - $56.17 $31,103 - $45,890	-817 Reduced 2.57%	30,973 $0
Q1 2021 May 13, 2021	BUY	$32.41 - $70.91 $1.03 Million - $2.25 Million	31,790 New	31,790 $0

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $63.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.